Navigation Links
Mylan Reports Adjusted Diluted EPS of $0.16 for the Quarter Ended June 30, 2008
Date:8/6/2008

d to the acquisition and integration of Merck Generics (e.g., non-recurring professional and consulting fees, retention and other non-recurring expenses).

(3) Tax effect for the three months ended June 30, 2008 is calculated assuming an annual effective tax rate. This tax rate, excluding any tax synergies, remains within the previously disclosed 36-38% range.

Conference Call

Mylan will host a conference call and live webcast today, Wednesday, August 6, 2008 at 10:30 a.m. ET, in conjunction with the release of its financial results. The dial-in number to access the call is 877-741-4241 or 719-325-4787 for international callers. To access the live webcast please go to Mylan's website at http://www.mylan.com and click on the webcast icon at least 15 minutes before the event is scheduled to begin to register and download or install any necessary software. A replay, available for approximately seven days, will be available at 888-203-1112 or 719-457-0820 for international callers, with access pass code 8142044. The live webcast and replay, which will be available for approximately seven days, will be accessible at http://www.mylan.com.

About Mylan

Mylan Inc., with a presence in more than 90 countries, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest-and highest quality-product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's second largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information about Mylan, please visit http://www.mylan.com.

Forward Looking Statements

This press release includes statements that constitute "forward-looking state
'/>"/>

SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Mylan Announces Final FDA Approval for Carvedilol Tablets
3. Mylan Announces Tentative FDA Approval for Topiramate Capsules
4. Mylan Announces Appointment of M. Fabiana Lacerca as Senior Vice President and Chief Compliance Officer
5. Mylan Announces Extension of Tender Offers for Its 5.750% Senior Notes due 2010 and 6.375% Senior Notes due 2015
6. Mylan Announces Appointment of David A. Lillback as Senior Vice President and Global Head of Human Resources
7. Mylan Announces Appointment of Brian Byala as Senior Vice President and Treasurer
8. Mylan Announces Appointment of Didier Barret as President, Europe, Middle East and Africa
9. Mylan Announces Appointment of Harry A. Korman as President, North America
10. Mylan Announces Appointment of John Montgomery as President, Asia Pacific
11. Mylan Announces Management of Specialty Business, Dey L.P.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)ANAHEIM, Calif., Dec. 4 Pamela Bowen, Chief Information Officer at Crescent Healthcare, was selected as a finalist for the "Chief Innovation Officer" Appy Award for transforming Crescent,s business w
(Date:12/4/2009)WASHINGTON, Dec. 4 In response to the U.S. Justice Department Drug Enforcement Agency,s (DEA) classification of boldione, desoxymethyltestosterone, and 19-nor-4,9(10)-androstadienedione as "anabolic
(Date:12/4/2009)STANFORD, Calif. A new study shows that muscle cells grown in the lab can restore an intestine,s ability to squeeze shut properly. The work, performed in dogs and rats, might ultimately help treat pa
(Date:12/4/2009)Case Western Reserve University researchers, from the School of Medicine,s Department of Nutrition, discovered two new metabolic pathways by which products of lipid peroxidation and some drugs of abus
(Date:12/4/2009)Rockville, MD "Why is it that men can be bastards and women must wear pearls and smile?" wrote author Lynn Hecht Schafran. The answer, according to an article in the Journal of Vision , may lie in
Breaking Medicine News(10 mins):Health News:Crescent CIO '09 Dreamforce Conference Speaker and Award Finalist 2Health News:Natural Products Association Issues Statement on DEA's Steroid Classification Action 2Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 2Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 3Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 4Health News:Case Western Reserve researchers' new pathway discovery published as 'Paper of the Week' 2Health News:Are angry women more like men? 2
... Houston-based Law Firm Offers Assistance...bri Effects. , Houston, T...awyers Pulaski & Middleman announce the launch...abri (natalizumab)., , ,Tysabri, a drug used to tr...
...1 The federal Centers for,Disease Control and Pre...of,annual new cases of HIV infections will be reve... of the American Medical Association (JAMA). The,r... revised estimate for 2006 will replace the curren...
...th glioblastoma multiforme (GBM), one of the most ... poor prognosis. Although pre-clinical studies ind... known as receptor tyrosine kinases (RTKs) would l...to such treatment and most subsequently relapse af...
..."convenience to home or work" as the main reason t... recent study conducted by researchers at the Univ...t Center in Cincinnati, OH. , The study included...y C. Mahoney, MD, lead author of the study. , Th...
...g. 1 Veridex, LLC announced today it,has complete...ially all of,the assets of Immunicon Corporation (...sidiaries., The assets acquired include intellect...ate the detection and enumeration,of circulating t...
...PRNewswire-FirstCall/ - Transition Therapeutics In... TSX:TTH) reports today that,there are no undisclo...olving the Company to account for its recent chang...ions with large markets. Transition,s lead,product...
Other Medicine News:Health News:Tysabri Lawyers Pulaski & Middleman Launch Web Resource Center for Patients Suffering from Tysabri Side Effects 2Health News:Estimate of Annual HIV Incidence Increases Significantly; New Estimate Will Show Need For a National AIDS Strategy 2Health News:Estimate of Annual HIV Incidence Increases Significantly; New Estimate Will Show Need For a National AIDS Strategy 3Health News:Transition Therapeutics Announces No Material Change 2
(Date:12/3/2009)WILMINGTON, Del., Dec. 3 ParagonRx, a Delaware-based company specializing in pharmaceutical risk management and optimal medication use, will host a free webinar on Wednesday, Dec. 9, on the FDA,s dra
(Date:12/3/2009)FORT WORTH, Texas, Dec. 3 Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM), a rapidly growing provider of specialty medical products, announced today an agreement with the Health In
(Date:12/3/2009)COSTA MESA, Calif., Dec. 3 TROY Group, Inc., a Worldwide Leader in Secure on-Demand Printing Solutions, announces the addition of the TROY 3015 SecureRx(TM) Printer to its line of secure prescripti
Breaking Medicine Technology:Wound Management Technologies, Inc. Signs Agreement with Major Sales Representative Organization for Increased Marketing of CellerateRx(R); Third Quarter Sales Up 2Wound Management Technologies, Inc. Signs Agreement with Major Sales Representative Organization for Increased Marketing of CellerateRx(R); Third Quarter Sales Up 3New TROY SecureRx Prescription Printer Marks 50th Hospital Installation Milestone 2MediciGlobal Wins Four International 2009 Communications Awards for Patient Recruitment and Retention 49256 1MediciGlobal Wins Four International 2009 Communications Awards for Patient Recruitment and Retention 49256 2Texas Institute for Surgery at Presbyterian Hospital of Dallas Introduces the First Wireless OR in DFW 49253 1Texas Institute for Surgery at Presbyterian Hospital of Dallas Introduces the First Wireless OR in DFW 49253 2National Minority Quality Forum to Release Groundbreaking National HIV AIDS Atlas 49249 1National Minority Quality Forum to Release Groundbreaking National HIV AIDS Atlas 49249 2
...nt Infusion Study in Patients with,Chronic Decompe...lege of Cardiology 56th Annual Scientific Session ...5, 2007,/PRNewswire/ -- Scios Inc. announced today...f nesiritide (NATRECOR(R)) showed a,neutral effect...,cardiorenal hospitalization at 12 weeks, and prov...
... Technology Holds Promise as,Future-Generation Tre...h Coronary Artery Disease, ABBOTT PARK, Ill., Marc...announced positive results from ABSORB, the world,...ty and performance,of a fully bioabsorbable drug- ...ry artery disease. Six- month results from the,fir...
Other Medicine Technology:Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 2Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 3Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 4Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 5Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 6Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 7Abbott Announces Positive Six-Month Results From the World's First,Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent 2Abbott Announces Positive Six-Month Results From the World's First,Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent 3
Lap Disc Hand Access Device
SleepStyle 232
ResMed S7™ Lightweight CPAP Device
REMstar Pro with C-Flex
Medicine Products: